Pinpin Sui, Ph.D.

• Professional Background

  Education

  • 2020 - PhD - Genomics - University of Chinese Academy of Sciences, Beijing, China
  • 2015 - BS - Bioinformatics - Harbin Medical University, Heilongjiang, China

  Training

  • 2022 - Postdoctor(Special Research Assistant) - Precision Medicine for Leukemia - Beijing Genomics Institute(China National Center for Bioinformation), Chinese Academy of Sciences

  Appointments

  • 2022-present - Instructor/Research - UT health San Antonio
  • 2020-2022 - Postoctor(Specical Research Assistant) - Beijing Genomics Institute(China National Center for Bioinformation), Chinese Academy of Sciences

• Research & Grants

  My study currently focues on the epigenetic regulatory mechanisms of key genes in normal and malignant hematopoiesis. My work is also dedicated to explore new treatment strategies for hematopoietic malignances based on the abnormal epigenetic regulation driven by the mutations of ASXL1, PHF6 and other dirver mutations.

• Publications

  • INTS11 regulates hematopoiesis by promoting PRC2 function
  • Benzene induces rapid leukemic transformation after prolonged hematotoxicity in a murine model
  • Ecological principle meets cancer treatment: treating children with acute myeloid leukemia with low-dose chemotherapy
  • Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
  • Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia
  • Three-dimensional chromatin landscapes in MLLr AML
  • SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis
  • Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models
  • Loss of BRD4 induces cell senescence in HSC/HPCs by deregulating histone H3 clipping